Director, Drug Safety Operations

Director, Clinical Development Scientist

Senior Medical Director, Drug Safety and Pharmacovigilance

Senior Clinical Data Manager

Senior Director, Biostatistics

Senior Director, Clinical Development

1910 Genetics

20n Bio

3DBio Therapeutics

3T Biosciences

4D Molecular Therapeutics

64x Bio

76Bio

A-Alpha Bio

A2 Biotherapeutics

AAVogen

ACELYRIN

AI Proteins

AIRNA Bio

ALX Oncology

AN2 Therapeutics

AOA Dx

ARTBIO

AUM BioTech

AVROBIO

Ab Studio

Abalone Bio

Abata Therapeutics

Abeona Therapeutics

Abintus Bio

Abiosciences

Absci

Accelevir Diagnostics

Accent Therapeutics

Acepodia

Achieve Life Sciences

Acomhal Research

Acrivon Therapeutics

Actym Therapeutics, Inc.

Acutis Diagnostics

Adaptive Phage Therapeutics

Adcentrx Therapeutics

Adicet Bio

Aditum Bio

Admera Health

Adverum Biotechnologies

Aeglea BioTherapeutics

Aether Bio

Affini-T Therapeutics

Affinia Therapeutics

Affinivax

AgBiome

Agastiya Biotech

Agena Bioscience

AiViva Biopharma

Ainnocence

AivoCode

Aixa Bio

Akero Therapeutics

Akita Biosciences

Akouos

Alamar Biosciences

Alector

Alida Biosciences

AlivaMab Discovery Services

Alkahest

Alladapt Immunotherapeutics

Allakos

Allarta Life Science

Allay Therapeutics

AlloVir

Alloy Therapeutics

Alltrna

AlpaLifeBio

Alpha-9 Oncology

Alphabioregen

Alpine Immune Sciences

AltPep

Alterome Therapeutics

Altis Biosystems

Alto Neuroscience

Alumis

Alveo Technologies

Alveolus Bio

Alzheon

AmbAgon Therapeutics

Amberstone Biosciences

Amolyt Pharma

Amylyx Pharmaceuticals

AnHeart Therapeutics

Anagram Therapeutics

Ancora Biotech LLC

Andes

Andson Biotech

Anebulo Pharmaceuticals

Angiex

Angiocrine Bioscience

Anima Biotech

Ankyra

Annexon Biosciences

Anodyne Nanotech

Anokion

Ansa Biotechnologies

Antheia

Anthos Therapeutics

Apaxon Biotech LLC

Dianthus Therapeutics is developing novel Complement therapeutics to improve the quality of life of patients with autoimmune diseases. The Complement system is part of the innate immune response that can get activated in autoimmune diseases. Dianthus is designing selective monoclonal antibodies that target components of the Complement system to reduce their activity. The antibodies are modified to have a longer half-life, thus enabling therapeutics reduced dose levels and frequency. Dianthus’ pipeline is in preclinical stages, with the most advanced, DNTH103, targeting active Complement C1s. DNTH103 is selective for the active, not inactive, C1s which sets it apart from current antibody therapies and could offer a more convenient subcutaneous therapy for patients.

<p>Dianthus Therapeutics is developing novel Complement therapeutics to improve the quality of life of patients with autoimmune diseases. The Complement system is part of the innate immune response that can get activated in autoimmune diseases. Dianthus is designing selective monoclonal antibodies that target components of the Complement system to reduce their activity. The antibodies are modified to have a longer half-life, thus enabling therapeutics reduced dose levels and frequency. Dianthus’ pipeline is in preclinical stages, with the most advanced, DNTH103, targeting active Complement C1s. DNTH103 is selective for the active, not inactive, C1s which sets it apart from current antibody therapies and could offer a more convenient subcutaneous therapy for patients.</p>


Find a biotech startup job.